System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Masatoshi Kudo is an expert in Oncology at Kindai University Hospital (Japan). As of October 2026, ScienceLeadR ranks Masatoshi Kudo in the top 1% of experts worldwide for Carcinoma, Liver Neoplasms and Endoscopy. Masatoshi Kudo has authored 1,941 publications, the most recent in 2026, and is an investigator in 45 clinical trials, 2 of them ongoing. SLR score: 8,268 (community average: 125). How the SLR is computed.

LeadR Profile

Masatoshi Kudo Kindai University Hospital Japan
8 268 ScienceLeadR Reputation 8268

Unlock

Register Login
Network Map

Oncology

Subspecialties: Hepatology - Gastroenterology - Medical Imaging

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1979 - 2026
Source: PubMed

Kobe City General Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1941

Citations

Citations: 106 514 1st author: 141 Last author: 695 Unique author: 154

Main journals

J Clin Oncol 161
Liver Cancer 157
Oncology 116
Dig Dis 95
Hepatol Res 78

Best Journals

J Clin Oncol 103
Ann Oncol 22
J Hepatol 18

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Hepatocellular carcinoma surveillance in Europe: challenges and lessons from global practice.
PMID 42819713 — carcinoma, hepatocellular, liver, diagnosis		Lancet Reg Health Eur20261
Nucleotide-binding oligomerization domain 2-independent colonization by Turicimonas muris induced by high-fat diet protects against dextran sodium sulfate-induced colitis.
PMID 42728835 — genes, colitis, diet, high-fat, diet, risk factors, mutation, microbiota		Clin Exp Immunol20260
Toward Global Harmonization of EUS-Guided Biliary Drainage: A Step Beyond Regional Consensus.
PMID 42677401 — drainage, endoscopy		Dig Endosc20260
Lenvatinib versus Sorafenib in First-Line Treatment of Older Patients with Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial.
PMID 42677015 — carcinoma, hepatocellular, safety, sorafenib, aged, therapeutics		Liver Cancer20260
Multiple Modes of Action of Anti-TNF-α Antibodies for Inflammatory Bowel Diseases Beyond TNF-α Neutralization.
PMID 42645428 — cytokines, cells, antibodies, macrophages, interleukin-12, inflammatory bowel diseases, adalimumab, apoptosis, infliximab		Antibodies (Basel)20260

Clinical Studies 45

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

Phase 3 26
Phase 2 8
Phase 1/Phase 2 5
N/A 2
Phase 2/Phase 3 2
Phase 1 1
Phase 4 1

By status:

Completed 29
Active not recruiting 8
Terminated 4
Unknown 4

By type:

Interventional 44
Observational 1

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 1
multicentric5to9 1
multicentricup10 37

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study Evaluating Atezolizumab and Bevacizumab With or Without Tiragolumab in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886 — carcinoma, hepatocellular, bevacizumab, therapeutics, carcinoma		Phase 3Active not recruiting2023
Evaluate Durvalumab and Tremelimumab Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842 — injections, carcinoma, hepatocellular, neoplasms, hepatic artery, arteries, liver, liver neoplasms, carcinoma		Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS